Affinity Asset Advisors, LLC Aldeyra Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $645,533 - $862,120	-105,652 Reduced 70.43%	44,348 $296,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $1.07 Million - $1.78 Million	150,000 New	150,000 $1.26 Million
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $327,466 - $520,924	-100,759 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$3.5 - $9.63 $339,500 - $934,110	-97,000 Reduced 49.05%	100,759 $403,000
Q3 2021 Nov 12, 2021	SELL	$7.94 - $11.31 $17,793 - $25,345	-2,241 Reduced 1.12%	197,759 $1.74 Million
Q2 2021 Aug 13, 2021	SELL	$10.44 - $14.85 $1.04 Million - $1.49 Million	-100,000 Reduced 33.33%	200,000 $2.27 Million
Q1 2021 May 14, 2021	BUY	$6.53 - $14.42 $1.31 Million - $2.88 Million	200,000 Added 200.0%	300,000 $3.56 Million
Q4 2020 Feb 12, 2021	BUY	$6.31 - $8.13 $631,000 - $813,000	100,000 New	100,000 $686,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $290M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.